#1 Clinical Trials Search in Europe

Lenvatinib

Lenvatinib, also known as E7080, is a promising drug being studied in various clinical trials for its potential in treating different types of cancer. This article explores the use of Lenvatinib in clinical trials, focusing on its effectiveness, safety, and applications in treating solid tumors, thyroid cancer, hepatocellular carcinoma, and other malignancies. The trials aim to determine optimal dosing, evaluate its efficacy alone and in combination with other treatments, and assess its potential as an adjuvant therapy.

Table of Contents

What is Lenvatinib?

Lenvatinib is a medication used in the treatment of various types of cancer. It’s also known by its brand names Lenvima™ and Keytruda®, as well as by its research code E7080[1][2]. Lenvatinib is classified as a targeted therapy, specifically a type of drug called a tyrosine kinase inhibitor. This means it works by blocking specific proteins that cancer cells need to grow and spread[2].

What Conditions Does Lenvatinib Treat?

Lenvatinib has been studied and used in the treatment of several types of cancer, including:

  • Differentiated Thyroid Cancer (DTC): This is a type of thyroid cancer that has not responded to radioactive iodine therapy[2].
  • Biliary Tract Cancer: This is a rare type of cancer that forms in the bile ducts[1].
  • Solid Tumors: These are cancers that form solid masses in the body, as opposed to blood cancers[3].
  • Non-small Cell Lung Cancer (NSCLC): This is the most common type of lung cancer[4].
  • Ovarian Clear Cell Carcinoma: This is a rare and aggressive type of ovarian cancer[5].

How Does Lenvatinib Work?

Lenvatinib works by targeting and blocking specific proteins (called tyrosine kinases) that cancer cells need to grow and form new blood vessels. By blocking these proteins, Lenvatinib can slow down or stop the growth of cancer cells and prevent them from spreading to other parts of the body[2].

How is Lenvatinib Administered?

Lenvatinib is typically taken orally (by mouth) in the form of capsules. The dosage and frequency can vary depending on the specific condition being treated and the individual patient. In most clinical trials, Lenvatinib was administered once daily, with dosages ranging from 20mg to 24mg[2][1]. It’s important to take Lenvatinib exactly as prescribed by your doctor.

Lenvatinib in Clinical Trials

Lenvatinib has been the subject of numerous clinical trials to test its effectiveness and safety in treating various types of cancer. Some key findings from these trials include:

  • In a study of patients with differentiated thyroid cancer, Lenvatinib significantly improved progression-free survival (the time during which the cancer did not worsen) compared to a placebo[2].
  • A trial in patients with biliary tract cancer showed promising results in terms of tumor response and disease control[1].
  • Studies have also explored the use of Lenvatinib in combination with other cancer treatments, such as chemotherapy drugs like carboplatin and paclitaxel[4].

Potential Side Effects

Like all medications, Lenvatinib can cause side effects. Common side effects reported in clinical trials include:

  • High blood pressure
  • Diarrhea
  • Fatigue
  • Decreased appetite
  • Weight loss
  • Nausea

It’s important to discuss potential side effects with your healthcare provider. They can provide guidance on managing side effects and may adjust your dosage if necessary[1][2].

Lenvatinib in Combination Therapy

Researchers are also studying Lenvatinib in combination with other cancer treatments. For example:

  • A study is exploring the combination of Lenvatinib with Pembrolizumab (another cancer drug) in treating ovarian clear cell carcinoma[5].
  • Another trial is investigating Lenvatinib in combination with carboplatin and paclitaxel (common chemotherapy drugs) in non-small cell lung cancer[4].

These combination therapies aim to enhance the effectiveness of cancer treatment by targeting cancer cells in multiple ways simultaneously.

Aspect Details
Cancer Types Studied Non-small cell lung cancer, solid tumors, differentiated thyroid cancer, hepatocellular carcinoma, osteosarcoma
Administration Oral capsules or liquid suspension, dosage varies by trial
Combination Therapies Studied with carboplatin, paclitaxel, ifosfamide, etoposide
Key Outcomes Measured Maximum tolerated dose, progression-free survival, overall survival, objective response rate, safety profile
Common Side Effects Hypertension, proteinuria, fatigue, diarrhea, hand-foot syndrome
Special Applications Adjuvant therapy for hepatocellular carcinoma after surgery
Patient Populations Adults with various solid tumors, children and young adults with osteosarcoma

FAQ

  • What types of cancer is Lenvatinib being studied for? Lenvatinib is being studied for various types of cancer, including non-small cell lung cancer, solid tumors, differentiated thyroid cancer, hepatocellular carcinoma, and osteosarcoma in children and young adults.
  • How is Lenvatinib administered in clinical trials? Lenvatinib is typically administered orally, either as capsules or in a liquid suspension form. The dosage and frequency may vary depending on the specific trial and patient characteristics.
  • What are some common side effects of Lenvatinib observed in clinical trials? Common side effects of Lenvatinib include hypertension, proteinuria, fatigue, diarrhea, and palmar-plantar erythrodysaesthesia syndrome (hand-foot syndrome). The severity and frequency of side effects are closely monitored in the trials.
  • Is Lenvatinib being studied in combination with other treatments? Yes, some clinical trials are investigating Lenvatinib in combination with other treatments. For example, it has been studied in combination with carboplatin and paclitaxel for non-small cell lung cancer, and with ifosfamide and etoposide for osteosarcoma.
  • What is the goal of using Lenvatinib as an adjuvant therapy? The goal of using Lenvatinib as an adjuvant therapy, such as in hepatocellular carcinoma after surgery, is to reduce the risk of cancer recurrence and improve survival rates in patients who have undergone primary treatment.

Ongoing Clinical Trials on Lenvatinib

  • Study on Pausing Treatment with Pembrolizumab and Axitinib in Patients with Metastatic Kidney Cancer at Good or Intermediate Risk

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Effectiveness of Lenvatinib for Patients with Advanced Gastrointestinal Stromal Tumors After Imatinib and Sunitinib Treatment Failure

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study Comparing Toripalimab and Lenvatinib with Placebo and Lenvatinib for First-Line Treatment in Patients with Advanced Liver Cancer

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy Poland

  • Study of Pembrolizumab with Lenvatinib after Chemoradiation Treatment in Patients with Locally Advanced Head and Neck Cancer who are PD-L1 Positive

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study of Pembrolizumab and Lenvatinib for Patients with Malignant Pleural Mesothelioma in Second and Third Line Treatment

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on Pembrolizumab, Etoposide, and Cisplatin or Carboplatin for First-Line Treatment in Patients with Extensive-Stage Small Cell Lung Cancer

    Not recruiting

    1 1 1
    Investigated drugs:
    Austria Hungary Italy Poland Spain

  • Study of MK-7684A and Pembrolizumab for Patients with Advanced Solid Tumors

    Not recruiting

    1 1 1
    Investigated drugs:
    France Germany Italy The Netherlands Poland Spain

  • Study on the Safety and Effectiveness of Pembrolizumab and Tretinoin in Patients with PD-1 Refractory Melanoma

    Not recruiting

    1 1 1
    Investigated drugs:
    France Greece Hungary Italy Poland Spain

  • Study of E7386 and Pembrolizumab for Patients with Previously Treated Colorectal Cancer, Melanoma, or Hepatocellular Carcinoma

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study of Nivolumab and Ipilimumab for Patients with Advanced Liver Cancer (Hepatocellular Carcinoma) as First-Line Treatment

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium France Germany Italy Poland +2

Glossary

  • Lenvatinib: A multi-targeted tyrosine kinase inhibitor used in cancer treatment, also known as E7080 or Lenvima.
  • Maximum Tolerated Dose (MTD): The highest dose of a drug that does not cause unacceptable side effects in a clinical trial.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.
  • Dose-Limiting Toxicity (DLT): Side effects of a drug that are severe enough to prevent an increase in dose or require a decrease in dose.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Adjuvant Therapy: Additional cancer treatment given after the primary treatment to lower the risk of cancer recurrence.
  • Hepatocellular Carcinoma (HCC): The most common type of primary liver cancer.

References

  1. https://clinicaltrials.gov/study/NCT02579616
  2. https://clinicaltrials.gov/study/NCT01321554
  3. https://clinicaltrials.gov/study/NCT00280397
  4. https://clinicaltrials.gov/study/NCT00832819
  5. https://clinicaltrials.gov/study/NCT05296512